{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:15:50Z","timestamp":1781712950891,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007941","name":"Addis Ababa University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The efficacies of artemisinin based combinations have been excellent in Africa, but also comprehensive evidence regarding their safety would be important. The aim of this review was to synthesize available evidence on the safety of dihydroartemisinin-piperaquine (DHA-PQ) compared to artemether-lumefantrine (AL) for the treatment of uncomplicated\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      malaria among children in Africa.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic literature search was done to identify relevant articles from online databases PubMed\/ MEDLINE, Embase, and Cochrane Center for Clinical Trial database (CENTRAL) for retrieving randomized control trials comparing safety of DHA-PQ and AL for treatment of uncomplicated\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      malaria among children in Africa. The search was performed from August 2020 to 30 April 2021. Using Rev-Man software (V5.4.1), the extracted data from eligible studies were pooled as risk ratio (RR) with 95% confidence interval (CI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this review, 18 studies were included, which involved 10,498 participants were included. Compared to AL, DHA-PQ was associated with a slightly higher frequency of early vomiting (RR 2.26, 95% CI 1.46 to 3.50; participants\u2009=\u20097796; studies\u2009=\u200910; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%, high quality of evidence), cough (RR 1.06, 95% CI 1.01 to 1.11; participants\u2009=\u20098013; studies\u2009=\u200913; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%, high quality of evidence), and diarrhoea (RR 1.16, 95% CI 1.03 to 1.31; participants\u2009=\u20096841; studies\u2009=\u200911; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20098%, high quality of evidence) were more frequent in DHA-PQ treatment arm.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>From this review, it can be concluded that early vomiting, diarrhoea, and cough were common were significantly more frequent in patients who were treated with the DHA-PQ than that of AL, and both drugs are well tolerated. More studies comparing AL with DHA-PQ are needed to determine the comparative safety of these drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-021-04032-2","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T03:02:50Z","timestamp":1641265370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety of dihydroartemisinin-piperaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria among children in Africa: a systematic review and meta-analysis of randomized control trials"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9951-5762","authenticated-orcid":false,"given":"Dawit Getachew","family":"Assefa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden Dagnachew","family":"Zeleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wondwosen","family":"Molla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebiyu","family":"Mengistu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmedin","family":"Sefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andualem","family":"Mebratu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asresu Feleke","family":"Bate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etaferaw","family":"Bekele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizachew","family":"Yesmaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyasu","family":"Makonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"4032_CR1","volume-title":"World Malaria Report 2019","author":"WHO","year":"2019","unstructured":"WHO . World Malaria Report 2019. Geneva: World Health Organization; 2019."},{"key":"4032_CR2","volume-title":"Guidelines for treatment of malaria","author":"WHO","year":"2015","unstructured":"WHO. Guidelines for treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"4032_CR3","unstructured":"World malaria report 2020: 20 years of global progress and challenges. Geneva: World Health Organization; 2020."},{"key":"4032_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1475-2875-13-S1-P19","volume":"13","author":"MT Bretscher","year":"2014","unstructured":"Bretscher MT, Griffin JT, Hugo P, Baker M, Ghani A, Okell L. A comparison of the duration of post-treatment protection of artemether-lumefantrine, dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated malaria. Malar J. 2014;13:19.","journal-title":"Malar J"},{"key":"4032_CR5","first-page":"CD007483","volume":"2009","author":"D Sinclair","year":"2009","unstructured":"Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. 2009;2009:CD007483.","journal-title":"Cochrane Database Syst Rev"},{"key":"4032_CR6","volume-title":"World Malaria Report 2014","author":"WHO","year":"2014","unstructured":"WHO. World Malaria Report 2014. Geneva: World Health Organization; 2014."},{"key":"4032_CR7","first-page":"CD010927","volume":"2014","author":"B Zani","year":"2014","unstructured":"Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014;2014:CD010927.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"4032_CR8","first-page":"1128","volume":"4","author":"RM Fairhurst","year":"2016","unstructured":"Fairhurst RM, Dondorp AM. Artemisinin-resistant Plasmodium falciparum malaria. Microbiol Spectr. 2016;4(10):1128.","journal-title":"Microbiol Spectr"},{"key":"4032_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12936-017-1712-4","volume":"16","author":"MM Plucinski","year":"2017","unstructured":"Plucinski MM, Dimbu PR, Macaia AP, Ferreira CM, Samutondo C, Quivinja J, et al. Efficacy of artemether\u2013lumefantrine, artesunate\u2013amodiaquine, and dihydroartemisinin\u2013piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015. Malar J. 2017;16:62.","journal-title":"Malar J"},{"key":"4032_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12936-018-2290-9","volume":"17","author":"E Davlantes","year":"2018","unstructured":"Davlantes E, Dimbu PR, Ferreira CM, Florinda Joao M, Pode D, F\u00e9lix J, et al. Efficacy and safety of artemether\u2013lumefantrine, artesunate\u2013amodiaquine, and dihydroartemisinin\u2013piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. Malar J. 2018;17:144.","journal-title":"Malar J"},{"key":"4032_CR11","doi-asserted-by":"publisher","DOI":"10.30875\/50d27d62-en","volume-title":"World Malaria Report 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. World Malaria Report 2017. Geneva: World Health Organization; 2017."},{"key":"4032_CR12","first-page":"195","volume-title":"Uganda Clinical Guidelines. National Guidelines for Management of Common Conditions","author":"Ministry of Health, Uganda","year":"2016","unstructured":"Ministry of Health, Uganda. Uganda Clinical Guidelines. National Guidelines for Management of Common Conditions. Kampala: Ministry of Health; 2016. p. 195\u20139."},{"key":"4032_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.4269\/ajtmh.2011.11-0069","volume":"85","author":"M Makanga","year":"2011","unstructured":"Makanga M, Bassat Q, Falade CO, Premji ZG, Krudsood S, Hunt P, et al. Efficacy and Safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg. 2011;85:793\u2013804.","journal-title":"Am J Trop Med Hyg"},{"key":"4032_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12936-015-0744-x","volume":"14","author":"YA Ebstie","year":"2015","unstructured":"Ebstie YA, Zeynudin A, Belachew T, Desalegn Z, Suleman S. Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem\u00ae) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study. Malar J. 2015;14:236.","journal-title":"Malar J"},{"key":"4032_CR15","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1186\/1475-2875-8-S1-S6","volume":"8","author":"C Falade","year":"2009","unstructured":"Falade C, Manyando C. Safety profile of Coartem\u00ae: the evidence base. Malar J. 2009;8:S6.","journal-title":"Malar J"},{"key":"4032_CR16","unstructured":"European Medicines Agency. Eurartesim (dihydroartemisinin\/piperaquine) 20 mg\/160 mg and 40 mg\/320 mg film-coated tablets: EU summary of product characteristics [online]. 2017."},{"key":"4032_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12936-021-03873-1","volume":"20","author":"DG Assefa","year":"2021","unstructured":"Assefa DG, Yismaw G, Makonnen E. Efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria among children in Africa: a systematic review and meta-analysis of randomized control trials. Malar J. 2021;20:340.","journal-title":"Malar J"},{"key":"4032_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijid.2021.10.013","volume":"113","author":"DG Assefa","year":"2021","unstructured":"Assefa DG, Yismaw G, Makonnen E. Comparative effect of dihydroartemisinin-piperaquine and artemether-lumefantrine on gametocyte clearance and haemoglobin recovery in children with uncomplicated Plasmodium falciparum malaria in Africa: a systematic review and meta-analysis of randomized control trials. Int J Infect Dis. 2021;113:136\u201347.","journal-title":"Int J Infect Dis"},{"key":"4032_CR19","unstructured":"Assefa DG, Zeleke ED, Molla W, Mengistu N, Sefa A, Mebratu A, et al. Systematic review and meta-analysis of the efficacy and safety of Dihydroartemisinin Piperaquine versus Artemether-Lumefantrine for the treatment of uncomplicated falciparum malaria in African children. PROSPERO. 2020. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020200337."},{"key":"4032_CR20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"4032_CR21","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, 2011. www.cochrane-handbook.org."},{"key":"4032_CR22","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"4032_CR23","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). 2021. www.training.cochrane.org\/handbook."},{"key":"4032_CR24","unstructured":"Deeks JJ, Higgins JPT, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., Eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). 2021. www.training.cochrane.org\/handbook."},{"key":"4032_CR25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74:785\u201394.","journal-title":"Biometrics"},{"key":"4032_CR26","unstructured":"McMaster University GRADEproGDT. McMasterUniversity (developed by Evidence Prime), 2020. https:\/\/gradepro.org\/."},{"key":"4032_CR27","unstructured":"Sch\u00fcnemann, Bro\u017cek, Guyatt, Oxman. Introduction to GRADE Handbook (Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach), 2013. https:\/\/gradepro.org."},{"key":"4032_CR28","unstructured":"Higgins JPT, SavovicJ, PageMJ, ElbersRG, Sterne JAC . Chapter 8: Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews ofInterventions version 6.0 (updated July 2019). 2019. www.training.cochrane.org\/handbook."},{"key":"4032_CR29","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence\u2013imprecision. J Clin Epidemiol. 2011;64:1283\u201393.","journal-title":"J Clin Epidemiol"},{"key":"4032_CR30","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1371\/journal.pctr.0020020","volume":"2","author":"MR Kamya","year":"2007","unstructured":"Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials. 2007;2:e20.","journal-title":"PLoS Clin Trials"},{"key":"4032_CR31","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1086\/522985","volume":"45","author":"I Zongo","year":"2007","unstructured":"Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis. 2007;45:1453\u201361.","journal-title":"Clin Infect Dis"},{"key":"4032_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/1475-2875-7-237","volume":"7","author":"PF Mens","year":"2008","unstructured":"Mens PF, Sawa P, van Amsterdam SM, Versteeg I, Omar SA, Schallig HD, et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J. 2008;7:237.","journal-title":"Malar J"},{"key":"4032_CR33","doi-asserted-by":"publisher","first-page":"e2390","DOI":"10.1371\/journal.pone.0002390","volume":"3","author":"A Yeka","year":"2008","unstructured":"Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS ONE. 2008;3:e2390.","journal-title":"PLoS ONE"},{"key":"4032_CR34","doi-asserted-by":"publisher","first-page":"e7871","DOI":"10.1371\/journal.pone.0007871","volume":"4","author":"Q Bassat","year":"2009","unstructured":"Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children. A randomised, non-inferiority trial. PLoS ONE. 2009;4:e7871.","journal-title":"PLoS ONE"},{"key":"4032_CR35","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1086\/647946","volume":"49","author":"E Arinaitwe","year":"2009","unstructured":"Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis. 2009;49:1629\u201337.","journal-title":"Clin Infect Dis"},{"key":"4032_CR36","doi-asserted-by":"publisher","first-page":"e26005","DOI":"10.1371\/journal.pone.0026005","volume":"6","author":"S Borrmann","year":"2011","unstructured":"Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS ONE. 2011;6:e26005.","journal-title":"PLoS ONE"},{"key":"4032_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1475-2875-10-50","volume":"10","author":"M Nambozi","year":"2011","unstructured":"Nambozi M, Van Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, et al. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J. 2011;10:50.","journal-title":"Malar J"},{"key":"4032_CR38","doi-asserted-by":"publisher","first-page":"e1001119","DOI":"10.1371\/journal.pmed.1001119","volume":"8","author":"Four Artemisinin-Based Combinations Study Group","year":"2011","unstructured":"Four Artemisinin-Based Combinations Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8:e1001119.","journal-title":"PLoS Med"},{"key":"4032_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/1475-2875-12-254","volume":"12","author":"A Agarwal","year":"2013","unstructured":"Agarwal A, McMorrow M, Onyango P, Otieno K, Odero C, Williamson J, et al. A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria among children in western Kenya. Malar J. 2013;12:254.","journal-title":"Malar J"},{"key":"4032_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1475-2875-13-33","volume":"13","author":"BR Ogutu","year":"2014","unstructured":"Ogutu BR, Onyango KO, Koskei N, Omondi EK, Ongecha JM, Otieno GA, et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study. Malar J. 2014;13:33.","journal-title":"Malar J"},{"key":"4032_CR41","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1128\/AAC.02682-14","volume":"58","author":"MA Onyamboko","year":"2014","unstructured":"Onyamboko MA, Fanello CI, Wongsaen K, Tarning J, Cheah PY, Tshefu KA, et al. Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo. Antimicrob Agents Chemother. 2014;58:5528\u201336.","journal-title":"Antimicrob Agents Chemother"},{"key":"4032_CR42","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/cid\/ciu286","volume":"59","author":"A Kakuru","year":"2014","unstructured":"Kakuru A, Achan J, Muhindo MK, Ikilezi G, Arinaitwe E, Mwangwa F, et al. Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Clin Infect Dis. 2014;59:446\u201353.","journal-title":"Clin Infect Dis"},{"key":"4032_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12936-014-0521-2","volume":"14","author":"AM Nji","year":"2015","unstructured":"Nji AM, Ali IM, Moyeh MN, Ngongang EO, Ekollo AM, Chedjou JP, et al. Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. Malar J. 2015;14:27.","journal-title":"Malar J"},{"key":"4032_CR44","doi-asserted-by":"publisher","first-page":"e0161495","DOI":"10.1371\/journal.pone.0161495","volume":"11","author":"J Ursing","year":"2016","unstructured":"Ursing J, Rombo L, Rodrigues A, Kofoed PE. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in children aged less than 15 years in Guinea-Bissau - an open-label non-inferiority randomised clinical trial. PLoS ONE. 2016;11:e0161495.","journal-title":"PLoS ONE"},{"key":"4032_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12936-018-2200-1","volume":"17","author":"F Grandesso","year":"2018","unstructured":"Grandesso F, Guindo O, WoiMesse L, Makarimi R, Traore A, Dama S, et al. Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi. Niger Malar J. 2018;17:52.","journal-title":"Niger Malar J"},{"key":"4032_CR46","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/infdis\/jiy637","volume":"219","author":"A Yeka","year":"2019","unstructured":"Yeka A, Wallender E, Mulebeke R, Kibuuka A, Kigozi R, Bosco A, et al. Comparative efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Ugandan children. J Infect Dis. 2019;219:1112\u201320.","journal-title":"J Infect Dis"},{"key":"4032_CR47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12936-021-03585-6","volume":"20","author":"A Gansan\u00e9","year":"2021","unstructured":"Gansan\u00e9 A, Moriarty LF, M\u00e9nard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018. Malar J. 2021;20:48.","journal-title":"Malar J"},{"key":"4032_CR48","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s12936-018-2494-z","volume":"17","author":"L Tavul","year":"2018","unstructured":"Tavul L, Hetzel MW, Teliki A, Walsh D, Kiniboro B, Rare L, et al. Efficacy of artemether\u2013lumefantrine and dihydroartemisinin\u2013piperaquine for the treatment of uncomplicated malaria in Papua New Guinea. Malar J. 2018;17:350.","journal-title":"Malar J"},{"key":"4032_CR49","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12936-021-03711-4","volume":"20","author":"DG Assefa","year":"2021","unstructured":"Assefa DG, Zeleke ED, Bekele D, Tesfahunei HA, Getachew E, Joseph M, et al. Efficacy and safety of dihydroartemisinin\u2013piperaquine versus artemether\u2013lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials. Malar J. 2021;20:174.","journal-title":"Malar J"},{"key":"4032_CR50","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.trstmh.2007.05.018","volume":"101","author":"HY Myint","year":"2007","unstructured":"Myint HY, Ashley EA, Day NP, Nosten F, White NJ. Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg. 2007;101:858\u201366.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"4032_CR51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12936-018-2524-x","volume":"17","author":"MA Kakolwa","year":"2018","unstructured":"Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, et al. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malar J. 2018;17:369.","journal-title":"Malar J"},{"key":"4032_CR52","doi-asserted-by":"publisher","first-page":"873","DOI":"10.4269\/ajtmh.2010.10-0158","volume":"83","author":"D Creek","year":"2010","unstructured":"Creek D, Bigira V, Arinaitwe E, Wanzira H, Kakuru A, Tappero J, et al. Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria. Am J Trop Med Hyg. 2010;83:873\u20135.","journal-title":"Am J Trop Med Hyg"},{"key":"4032_CR53","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1475-2875-10-198","volume":"10","author":"W Yavo","year":"2011","unstructured":"Yavo W, Faye B, Kuete T, Djohan V, Oga SA, Kassi RR, et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar J. 2011;10:198.","journal-title":"Malar J"},{"key":"4032_CR54","first-page":"e02473","volume":"65","author":"M Saito","year":"2021","unstructured":"Saito M, Yotyingaphiram W, Cargill Z, Gilder ME, Min AM, Phyo AP, et al. Electrocardiographic effects of four antimalarials for pregnant women with uncomplicated malaria on the Thailand-Myanmar border: a randomised controlled trial. Antimicrob Agents Chemother. 2021;65:e02473-e2520.","journal-title":"Antimicrob Agents Chemother"},{"key":"4032_CR55","doi-asserted-by":"publisher","first-page":"6056","DOI":"10.1128\/AAC.02667-14","volume":"58","author":"J Manning","year":"2014","unstructured":"Manning J, Vanachayangkul P, Lon C, Spring M, So M, Sea D, et al. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Chemother. 2014;58:6056\u201367.","journal-title":"Antimicrob Agents Chemother"},{"key":"4032_CR56","doi-asserted-by":"publisher","first-page":"e0174503","DOI":"10.1371\/journal.pone.0174503","volume":"12","author":"AR Oduro","year":"2017","unstructured":"Oduro AR, Owusu-Agyei S, Gyapong M, Osei I, Adjei A, Yawson A, et al. Post-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana. PLoS ONE. 2017;12:e0174503.","journal-title":"PLoS ONE"},{"key":"4032_CR57","doi-asserted-by":"publisher","first-page":"e0164851","DOI":"10.1371\/journal.pone.0164851","volume":"11","author":"AM Kabanywanyi","year":"2016","unstructured":"Kabanywanyi AM, Baiden R, Ali AM, Mahende MK, Ogutu BR, Oduro A, et al. Multi-country evaluation of safety of dihydroartemisinin\/piperaquine post-licensure in African public hospitals with electrocardiograms. PLoS ONE. 2016;11:e0164851.","journal-title":"PLoS ONE"},{"key":"4032_CR58","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12936-020-03309-2","volume":"19","author":"LE Mhamilawa","year":"2020","unstructured":"Mhamilawa LE, Wikstr\u00f6m S, Mmbando BP, Ngasala B, M\u00e5rtensson A. Electrocardiographic safety evaluation of extended artemether-lumefantrine treatment in patients with uncomplicated Plasmodium falciparum malaria in Bagamoyo District. Tanzania Malar J. 2020;19:250.","journal-title":"Tanzania Malar J"},{"key":"4032_CR59","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1473-3099(18)30297-4","volume":"18","author":"XHS Chan","year":"2018","unstructured":"Chan XHS, Win YN, Mawer LJ, Tan JY, Brugada J, White NJ. Risk of sudden unexplained death after use of dihydroartemisinin\u2013piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infect Dis. 2018;18:913\u201323.","journal-title":"Lancet Infect Dis"},{"key":"4032_CR60","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12936-019-2909-5","volume":"8","author":"E Sevene","year":"2019","unstructured":"Sevene E, Banda CG, Mukaka M, Maculuve S, Macuacua S, Vala A, et al. Efficacy and safety of dihydroartemisinin\u2013piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial. Malar J. 2019;8:277.","journal-title":"Malar J"},{"key":"4032_CR61","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41598-018-37112-6","volume":"9","author":"C Funck-Brentano","year":"2019","unstructured":"Funck-Brentano C, Bacchieri A, Valentini G, Pace S, Tommasini S, Voiriot P, et al. Effects of dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine on QTc interval prolongation. Sci Rep. 2019;9:777.","journal-title":"Sci Rep"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-04032-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-04032-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-04032-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T10:22:07Z","timestamp":1650277327000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-04032-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4032"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-04032-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-746101\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-746101\/v2","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"28 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}